Eton Pharmaceuticals, an innovative pharmaceutical company focused on developing and commercializing rare disease treatments, announced that it had acquired Galzin (zinc acetate).
Galzin is FDA-approved as a maintenance treatment of patients with Wilson Disease who was initially treated with a chelating agent. And it is estimated that less than 5,000 patients in the US are currently being treated for Wilson Disease.
Eton expects to assume the commercialization of the product in the US in the first quarter of 2025 with its metabolic sales force supporting healthcare professionals who treat Wilson Disease. After available, Eton plans to offer the product through its Eton Cares patient support program that provides high-touch, personalized service tailored for rare disease patients and their providers.
This program will offer a $0 co-pay for all qualified commercial patients, provide prescription fulfillment, insurance benefits investigation, educational support, and other services designed to help patients access treatment.
As part of the deal, Eton has also acquired European rights to the product, where it is commercialized under the tradename Wilzin by a third party. And under an existing distribution agreement, Eton will continue to supply the product to the third party and the third party is responsible for all commercialization activities in Europe.
Stifel served as the exclusive financial advisor to Eton on the transaction. Law firm Morrison Foerster advised Eton Pharmaceuticals.
KEY QUOTES:
“This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra rare patient populations. Galzin is a critical medication for patients with Wilson Disease, and we look forward to supporting these patients with our comprehensive Eton Cares patient support program.”
– Sean Brynjelsen, CEO of Eton Pharmaceuticals
